Neurotoxic effects are seen in patients using lithium regardless of dose. The neuroprotective activity of metformin used in the treatment of patients with type 2 diabetes mellitus is known. In this study, the protective efficacy of metformin against the neurotoxic effects of lithium was investigated. Neurotoxicity was induced by administering high dose oral lithium (40 mmol/kg) to rats for two weeks. Four groups were formed, with 6 rats in each group. OSI indices were calculated by measuring serum TAS and TOS levels. TAS, TOS, OSI, Gpx ADAM10, and ADAM17 levels were measured in the brain tissue. The neuroprotective activity of metformin was examined histopathologically by calculating the pyknosis scores, vacuolization, and interstitial edema in the hippocampus and cortex tissues. When lithium and metformin were given together, serum levels of TAS, TOS, and OSI were lower than that of the Lithium group (p
Key words: Lithium, metformin, neurotoxicity, ADAM10, ADAM17
|
